ライフサイエンスコーパス: manufacturer

1 d positivity cutoffs by each assay developer/manufacturer).

2 , respectively, spanning claims made by each manufacturer.

3 sment process that had been used by the food manufacturer.

4 or the degree of polymerization (DP) and the manufacturer.

5 hat according to the label were added by the manufacturer.

6 management decision(s) that are made by food manufacturer.

7 on depending on both the bottle position and manufacturer.

8 ariability and then were stratified by assay manufacturer.

9 10(5)-fold lower than those reported by the manufacturer.

10 ance values, even between lots from the same manufacturer.

11 of the gun shot residue with respect to the manufacturer.

12 ifficulty recognizing the chest radiographs' manufacturer.

13 ders including patients, clinicians, and the manufacturer.

14 on than they were from each other individual manufacturer.

15 nt exacting legal reparations against opioid manufacturers.

16 l as Glu-PLGAs obtained from three different manufacturers.

17 and II between intensity parameters of the 2 manufacturers.

18 vity and interdependency among suppliers and manufacturers.

19 antimicrobial susceptibility testing device manufacturers.

20 3 orders of magnitude in filaments from two manufacturers.

21 o image quality and is tested with different manufacturers.

22 elevant regulatory bodies and medical device manufacturers.

23 erest for scientists, food or pharmaceutical manufacturers.

24 ssociation between drug prices and number of manufacturers.

25 distributed to Australasian food and grocery manufacturers.

26 h 2016, reference mining, and pharmaceutical manufacturers.

27 s of cleaning in place systems (CIP) of food manufacturers.

28 were generally lower than those reported by manufacturers.

29 vely associated with the number of available manufacturers.

30 the rate tested in clinical trials for some manufacturers.

31 umina is one of the largest genotyping array manufacturers.

32 position could offer opportunities for dairy manufacturers.

33 dressed by a large number of diagnostic test manufacturers.

34 the cutoff levels suggested by the test kit manufacturers.

35 the presence of formulations from two other manufacturers.

36 holds, application of confirmation step, and manufacturers.

37 h 2016, reference mining, and pharmaceutical manufacturers.

38 cificities, thresholds, test variations, and manufacturers.

39 t 7 among PZ lesions at 3 T in data from two manufacturers.

40 physicians who received payments from device manufacturers.

41 es often directly negotiate drug prices with manufacturers.

42 production poses a waste and cost burden to manufacturers.

43 and rLP2086 (Trumenba; Pfizer, Inc.) vaccine manufacturers.

44 in peptides, and 1 for EMA, from 5 different manufacturers), 2 HLA-DQ2/DQ8 tests from 2 manufacturers

45 valence were 22.4% (95% CI, 21.9%-22.9%) for manufacturer A; 14.5% (95% CI, 14.0%-15.0%) for manufact

46 ent configurations (magnetic field strength, manufacturer, age).

47 ic harms for silicone/saline implants from 2 manufacturers (Allergan and Mentor) placed for primary/r

48 vent of platform technologies offers vaccine manufacturers an opportunity to develop new vaccines fas

49 Manufacturer analyses revealed a case of premature pacem

50 ise agreement between sequences while fixing manufacturer and field strength (n = 8).

51 references, and obtained data from the HBAT manufacturer and from the Centers for Disease Control an

52 dose (change in R(2) = 8%-32%), followed by manufacturer and iterative reconstruction (change in R(2

53 y manufacturer, which suggests that a single manufacturer and medium type should be selected for glob

54 We also screened the Manufacturer and User Facility Device Experience databas

55 ng to the survey, 92.5% of patrons, 73.7% of manufacturers and 96.7% of carpenters said timber adulte

56 g a genetic continuity within the Gravettian manufacturers and a discontinuity marked by the Last Gla

57 Joining forces of allergists, manufacturers and authorities are of high importance to

58 in separating TCM preparation from different manufacturers and batches with high accuracy; (2) classi

59 of which are serious concerns for chocolate manufacturers and consumers.

60 tracts varied over 10-fold between different manufacturers and fish species.

61 gh consumer demand has led global food color manufacturers and food companies to dramatically increas

62 16 and implemented in April 2018 and charges manufacturers and importers at pound 0.24 per litre for

63 Some of the cost of the levy to manufacturers and importers was passed on to consumers a

64 ed as unique cell products by many different manufacturers and laboratories, often under different co

65 The top 15 companies were all pharmaceutical manufacturers and paid dermatologists $28.7 million, rep

66 and their underlying principles by equipment manufacturers and pulmonary function laboratories can im

67 imum dose per treatment are set by fungicide manufacturers and regulators at a level that provides ef

68 ed to characterize these products and enable manufacturers and regulators to better determine potency

69 ces in gepotidacin disk results between disk manufacturers and some agar types and also with potassiu

70 chers, funding agencies, journals, equipment manufacturers and staff at shared imaging facilities are

71 ected libraries purchased from two different manufacturers and that the fate of the "biased sequences

72 lders (designers, policy-makers, and vehicle manufacturers and their material and component suppliers

73 rom Skyfire (a UAS consultancy), Vayu (a UAS manufacturer), and Sandia National Laboratories (a priva

74 (ie, use as an add-on to a statin) from the manufacturer, and 16% had prescribed it off-label for th

75 ng the gaps among material scientist, dental manufacturer, and clinical provider.

76 ding healthcare professionals, policymakers, manufacturers, and communities.

77 resonance (MR) imaging among readers, imager manufacturers, and field strengths.

78 t manufacturers), 2 HLA-DQ2/DQ8 tests from 2 manufacturers, and histopathology findings from the refe

79 m that brought together health care workers, manufacturers, and scientists to emergently develop and

80 collaboration with drug regulators, vaccine manufacturers, and the private sector for immunization-r

81 , but relies on collaboration between users, manufacturers, and the U.S. Food and Drug Administration

82 g the reduction of single-use plastics, some manufacturers are creating new plastic packaging to repl

83 Allergen manufacturers argue with increasing costs forcing them t

84 an orange concentrate, from a Spanish juice manufacturer, as well as in commercial orange juices and

85 lassified as commercial, Medicaid, Medicare, manufacturer assistance program, or other.

86 care, and $127 million (6.1%) for those with manufacturer assistance.

87 system according to the National Electrical Manufacturers Association (NEMA) NU2-2012 standard and t

88 were performed using the National Electrical Manufacturers Association 2007 image-quality phantom.

89 andard (published by the National Electrical Manufacturers Association [NEMA]) to allow for a reliabl

90 serts were placed in the National Electrical Manufacturers Association image-quality phantom and scan

91 Methods: A whole-body National Electrical Manufacturers Association image-quality phantom was imag

92 s work characterizes its National Electrical Manufacturers Association NU 4-2008 performance where ap

93 of the system using the National Electrical Manufacturers Association NU 4-2008 standard protocol.

94 e characterized with the National Electrical Manufacturers Association NU-2 2012 standards.

95 After reconstruction, National Electrical Manufacturers Association NU-4 tests examined uniformity

96 A National Electrical Manufacturers Association NU2 quality phantom was used f

97 e was measured using the National Electrical Manufacturers Association NU2-2012 methodology.

98 re measured based on the National Electrical Manufacturers Association NU2-2012 procedures.

99 The National Electrical Manufacturers Association tests revealed values within t

100 types (used in commercial aviation) from two manufacturers at thrust levels ranging from idle to take

101 iver biopsy and MRI (scanners from different manufacturers, at 1.5T or 3T).

102 ufacturer A; 14.5% (95% CI, 14.0%-15.0%) for manufacturer B; 18.8% (95% CI, 18.2%-19.4%) for manufact

103 e different commercial lots from three caMHB manufacturers (Becton, Dickinson; Oxoid; and Sigma-Aldri

104 5473 fresh cells from an automotive battery manufacturer before the cell-screening process.

105 e in the median NADAC price or the number of manufacturers between 2013 and 2016.

106 of irradiation) or supplied by a commercial manufacturer (bulk vial eluted from a generator).

107 at low cost and can be used not only by food manufacturers but also by regulatory agencies for better

108 metrics that are measured by default by the manufacturer, but also calculates other insightful measu

109 gher than type approval limit values for all manufacturers, but some perform systematically better th

110 ufacturer B; 18.8% (95% CI, 18.2%-19.4%) for manufacturer C; and 30.6% (95% CI, 30.0%-31.2%) for manu

111 Thus, sIPV products from different manufacturers cannot be compared, and the relationship b

112 e chest radiographs as belonging to a target manufacturer class.

113 ry LAAC procedure requires the presence of a manufacturer clinical specialist and for procedural para

114 consensus recommendations are presented for manufacturers, clinicians, operators, and researchers wi

115 Manufacturers, companies, and health care professionals

116 to have durably low costs, especially where manufacturer competition is lacking.

117 verall stable between 2013 and 2016, reduced manufacturer competition was associated with increased p

118 ncreases, and most, but not all, had limited manufacturer competition.

119 nt revenue per unit of the product after all manufacturer concessions are accounted for (including re

120 European TBE vaccines, as recommended by the manufacturers, consists of three vaccine doses administe

121 leic acid extraction control and an internal manufacturer control, GAPDH (glyceraldehyde-3-phosphate

122 (DE) CT acquisition schemes used by major CT manufacturers could aid researchers looking to use iodin

123 dults (>/=25 kg) after administration of the manufacturers' currently recommended dose regimens.

124 have positive or negative findings based on manufacturer cut-off values.

125 turer C; and 30.6% (95% CI, 30.0%-31.2%) for manufacturer D.

126 of copies per milliliter) using internal or manufacturer data.

127 ade 2 or greater in HIV-negative women using manufacturer-defined cycle threshold cutoffs for all cha

128 a product group were indicative of batch- or manufacturer-dependent variation.

129 Sports bra manufacturers designing wearable technology garments mus

130 t by the patient's insurance company-not the manufacturer, distributor, or pharmacy-and is typically

131 by 90% or more, and 13 (16%) had 2 or fewer manufacturers during all 4 years.

132 sted at one location using reagents from one manufacturer, each S. delphini strain tested positive fo

133 crucial to the decision while physicians and manufacturers expressed that the cost issue was secondar

134 Branded drug manufacturers face few barriers to exorbitant pricing of

135 small amounts of variability between imager manufacturers, field strengths, and pulse sequences.

136 ic PDFF measurements across all three imager manufacturer-field strength combinations also showed exc

137 colony size and color were apparent for each manufacturer for control E. coli strains.

138 While prices and the number of manufacturers for common oral antibiotics were overall s

139 all US Food and Drug Administration-approved manufacturers for each formulation and strength in 2013

140 re and more attracting the attention of food manufacturers for their potential to transform food in f

141 groups (A, B, C, and D) corresponding to the manufacturer from which the physician who performed the

142 compare changes in drug prices and number of manufacturers from 2013 to 2016.

143 he device as frequently as instructed by the manufacturer (>=3 tests per week); 24.7% of eyes discont

144 ergoing high-level disinfection according to manufacturers' guidelines.

145 However, patients, physicians, and the manufacturer had different opinions on the importance of

146 With this protocol, manufacturers have a means to report their UV LED specif

147 Mueller-Hinton broth (caMHB) from different manufacturers have been found to differ.

148 ation than free-base nicotine, and many ECIG manufacturers have begun marketing protonated nicotine p

149 In response, many diagnostic manufacturers have developed molecular assays for SARS-C

150 Aquafeed manufacturers have reduced, but not fully eliminated, fi

151 rs, pharmacy benefit managers, distributers, manufacturers, health systems, and pharmacies that toget

152 nspections of facilities at the saline flush manufacturer identified deficiencies that might have led

153 en) received ICD or CRT-D devices from the 4 manufacturers implanted by 4435 physicians at 1763 facil

154 hnologies" (COMET) to understand how vehicle manufacturers implement fuel economy technologies to com

155 and the proportion of devices from the same manufacturer in the entire study cohort (expected preval

156 ance data for multiple assays from different manufacturers in a single study population, which ultima

157 c and industrial partners, including vaccine manufacturers in developing countries.

158 agnostic tool in all autopsies and to assist manufacturers in identifying potentially fatal device fa

159 propose tessellating blanks for various car manufacturers in the same coil of steel to increase the

160 r RS, ROR, EP, and BCI were conducted by the manufacturers in the TransATAC sample collection that co

161 January 2018 with 10 scanners from a single manufacturer, including different models, at four differ

162 As financial risks to manufacturers increase even further with OPV cessation,

163 an ICD or CRT-D implantation than each other manufacturer individually.

164 t was then determined from ingredient lists, manufacturers' information and recipes.

165 irmation of samples not formally included in manufacturer instructions (i.e., nonvalidated) was 89.1%

166 ple types formally included according to the manufacturers' instructions (i.e., validated).

167 proportion morphologically suitable (within manufacturers' instructions for use) for EVAR (EVAR suit

168 n different diagnostic platforms, as per the manufacturers' instructions.

169 The manufacturer introduced a replacement surfactant hexaflu

170 While software by the manufacturer is available in addition to third parties p

171 ICD or CRT-D device from any of the 4 major manufacturers (January 1, 2016-December 31, 2018) were i

172 cially permitted off-label promotion after a manufacturer lawsuit.

173 idal self-assembly has been utilized to help manufacturers make better paint with less cost.

174 culated by summing the squares of individual manufacturers' market shares, with higher values indicat

175 Unscrupulous manufacturers may adulterate FMP with melamine or urea t

176 le pulse sequences provided by the MR imager manufacturers (mDIXON Quant [Philips Healthcare], IDEAL

177 for agreement between pulse sequences across manufacturers (n = 4) and field strengths (n = 5), respe

178 of vehicles equipped with original equipment manufacturer (OEM) diesel particulate filters (DPFs) in

179 in the real-world setting, sponsored by the manufacturer of omalizumab.

180 The primary outcome of the study was the manufacturer of the device used for the implantation.

181 t concern, it may require the pharmaceutical manufacturer of the drug in question to conduct a postma

182 developed by the Pharmaceutical Research and Manufacturers of America, and the Benefit-Risk Framework

183 EVAMP Act was proposed in Congress to reward manufacturers of certain novel antibiotics with transfer

184 levels have been demonstrated from all major manufacturers of dual-energy CT units.

185 Manufacturers of FDA-approved laboratory tests paid $12.

186 for EUA is currently a voluntary process for manufacturers of serologic assays.

187 Neither government regulators nor manufacturers of SGLT2 inhibitors evinced an awareness o

188 The manufacturers of the cdPCR and ddPCR systems available t

189 dicare and Medicaid Services; and commercial manufacturers of these products.

190 Manufacturers of US Food and Drug Administration-approve

191 veloped and tested in 14 facilities spanning manufacturers of UV LEDs and devices and research instit

192 (ML) classifiers tasked with recognizing the manufacturer on the basis of chest radiography inputs.

193 Modifiable factors including EVR graft manufacturer or supra-renal fixation were not associated

194 ld decide on the data to be presented by the manufacturer or the compounder and review those data, an

195 try national regulatory authorities, vaccine manufacturers, partner organizations, and relevant units

196 Manufacturers' payments to physicians who performed an I

197 List prices represent manufacturers' price to wholesalers or direct purchasers

198 ood and Drug Administration's rules limiting manufacturer promotion of prescription drugs for unappro

199 l sample-preparation kits are used following manufacturer protocols.

200 HPV testing followed the manufacturers' protocols.

201 The manufacturer provided vaccine and placebo in coded vials

202 d molecular weights available from different manufacturers provides a great variability in its physic

203 annot be assessed, this poses a challenge to manufacturers, public health authorities, and researcher

204 ns, 4152 (94%) received payments from device manufacturers ranging from $2 to $323 559 with a median

205 chest radiographs as belonging to the target manufacturer rather than to a native one.

206 cused on list prices, without accounting for manufacturer rebates and other discounts, which have sub

207 ions from US Food and Drug Administration or manufacturer recommendations for reprocessing.

208 eadtime reaching an asymptotic low where the manufacturer recommended voltage for operation falls.

209 erformance at various cutoffs found that the manufacturers' recommended cutoffs were diagnostically s

210 ng the concentration range observed with the manufacturers' recommended regimen.

211 superficial and deep vascular plexuses using manufacturer-recommended default settings are likely to

212 0 asymptomatic volunteers in accordance with manufacturer-recommended guidelines for CT lung cancer s

213 As are prescribed C- or J-shaped RSPs with a manufacturer-recommended stiffness category based on bod

214 ealth technical agencies and donors, vaccine manufacturers, regulatory agencies, World Health Organiz

215 ver, there is less quality control after the manufacturer releases the drug.

216 ts and establish active partnerships between manufacturers, relevant scientific societies, consumer o

217 ustry's uptake of the VITAL((R)) process, 25 manufacturers reported on factors that influenced the up

218 Manufacturers reported that 23% (95% CI 19-28) of produc

219 absolute differences between calculated and manufacturer-reported chlorination degrees were -0.9 to

220 ntial ESBL E. coli MacConkey agar from eight manufacturers, representing seven countries, was prepare

221 batteries may also present an opportunity as manufacturers require access to strategic elements and c

222 Further, the manufacturer's criteria for successful pre-amplification

223 and reported performance in reference to the manufacturer's cutoff and also to a threshold chosen to

224 Use of this test at the manufacturer's cutpoint in a population of 100000 with a

225 1 paper using the manufacturer's data, published pore-size distribution me

226 ot tested in a peer-reviewed trial for their manufacturer's ICDs.

227 ethods: Radiotracer preparation followed the manufacturer's indications.

228 was done using Zymogen Kit according to its manufacturer's instructions followed by amplifications w

229 The LFA was performed following the manufacturer's instructions using a cube reader to gener

230 The IMMY GM-EIA was performed following the manufacturer's instructions.

231 tested by the Alethia assay according to the manufacturer's instructions.

232 he Carba-R NxG and the Carba-R tests per the manufacturer's instructions.

233 ore randomization to the maximum dose on the manufacturer's label that did not cause unacceptable sid

234 lication of DDG that is available within the manufacturer's product), external device-based gating (r

235 tube 1 (TB1) or TB2 tested positive, per the manufacturer's recommendations, or if both TB1 and TB2 t

236 howed that initial MACS runs performed using manufacturer's recommended antibody and microbead concen

237 geing at low voltages, at and well below the manufacturer's recommended value.

238 ylamide formation in coffee, maintaining the manufacturer's requirements of the finished product.

239 ic actinomycetes using both the MALDI-TOF MS manufacturer's supplied database(s) and a custom databas

240 The CIED interrogation, the manufacturer's technical analysis, and the final autopsy

241 pecificity of 52% (95% CI, 40 to 64%) at the manufacturer's threshold of 10 mg/liter.

242 estigation of IR practices and review of the manufacturer's training video revealed sterility breache

243 discovered through WGS surveillance and the manufacturer's training video that demonstrated nonsteri

244 ere statistically indistinguishable from the manufacturer's values.

245 ived from a Webinar available to the public, manufacturer's websites, U.S. Food and Drug Administrati

246 n simply using thresholds recommended by the manufacturer, screening programs should choose threshold

247 reasonable expectations for what diagnostic manufacturers should be required to demonstrate to suppo

248 on from chest radiographs acquired using one manufacturer (Siemens) to chest radiographs acquired usi

249 Current Supplier-Manufacturer (SM) networks are highly complex and suscep

250 Manufacturer-specific factors interacted with fast detec

251 mplex and unanticipated interactions between manufacturer-specific features and generic programming c

252 In clinical trials, manufacturer-specific, strategic programming of implanta

253 ted in nonstandard configurations outside of manufacturer specifications.

254 rice compare at multiple pharmacies; (3) use manufacturer-supplied coupons to reduce out-of-pocket co

255 Currently quite a few manufacturers synthesize HMOs, however, their analysis i

256 e in proportional use of devices between the manufacturer that made the highest payment and the propo

257 ely to receive ICD or CRT-D devices from the manufacturer that provided the highest total payment to

258 n of patients who received a device from the manufacturer that provided the largest payment to the ph

259 y more likely to receive devices made by the manufacturer that provided the largest payment to the ph

260 54.7% of patients received devices from the manufacturers that had provided physicians with the larg

261 and Drug Administration issued guidances to manufacturers that resulted in Center for Medicare and M

262 my; thus, it has been of great importance to manufacturers that the aroma of their food product is ch

263 makers, funders, and vaccine developers and manufacturers the potential impact of efforts to reduce

264 collaboration between programme partners and manufacturers, the cessation of a supply market can be u

265 the pharmacovigilance databases of the DOAC manufacturers, the European Medicines Agency (EMA), the

266 rces to bridge the patient safety gap, while manufacturers, the FDA, and others determine how best to

267 sweaters: four from one name-brand clothing manufacturer (three majority polyester fleece, and one n

268 ostic performance for AN were made at preset manufacturers' thresholds (range, 2.0-17.0 mug Hb/g fece

269 ed to rely on residual stocks including with manufacturers through to the last campaign to achieve it

270 evidence-based detection parameters from one manufacturer to another.

271 y agencies require pharmaceutical and device manufacturers to conduct studies in the post-marketing p

272 more stringent guidelines for glucose meter manufacturers to evaluate the performance of blood gluco

273 ary incentives for pharmaceutical and device manufacturers to generate comparative data in the post-m

274 ceived, sufficient supply was awarded to two manufacturers to meet projected routine requirements.

275 ults suggest that the SDIL incentivised many manufacturers to reduce sugar in soft drinks.

276 Several incentives for manufacturers to sell alternative fuel vehicles (AFVs) h

277 The most important factor that allows manufacturers to set high drug prices is market exclusiv

278 significant losses in activity, which forces manufacturers to use large amounts of noble metals to en

279 It is of utmost importance that manufacturers update continuously values declared for pr

280 Several manufacturers use Sabin OPV strains for IPV production (

281 ve postharvest practices by consumers and/or manufacturers usually applied to produces before consump

282 rovide scientists, clinicians and healthcare manufacturers valuable information regarding the most re

283 ds, model years, curb weights, engine loads, manufacturers, vehicle age, and temperature, as well as

284 by rapid PYR methods with products from four manufacturers was performed at two testing locations, an

285 ry of E. coli 13457 from four MacConkey agar manufacturers was reduced by up to 4 log CFU/ml, and phe

286 sta beans with those declared on packages by manufacturers was verified.

287 of the labelling information declared by the manufacturers was within recommendations despite a degre

288 Together with a commercial scanner manufacturer, we developed a 4-bed mouse "hotel" to simu

289 infant and toddler foods was collected from manufacturers' websites and stores from May to July 2015

290 nal study, 29 automobiles from 15 automobile manufacturers were analyzed.

291 One hundred and thirty-seven Australasian manufacturers were contacted, and 59 questionnaires were

292 commercial fish extracts from five different manufacturers were examined.

293 ogy-approved phantom results between scanner manufacturers were similar.

294 al of 192 bottles from 32 bottle designs and manufacturers were tested.

295 reproducibility of MacConkey agar varied by manufacturer, which suggests that a single manufacturer

296 od will be of value to other researchers and manufacturers wishing to study biofilm growth and remova

297 esulted in classification of the penultimate manufacturer with an accuracy of 89%.

298 ated software solutions could be shared with manufacturers with the aim of including these in standar

299 ealth technical agencies and donors, vaccine manufacturers, World Health Organization and United Nati

300 h procedures have led to legal cases against manufacturers worldwide and to national inquiries about